Acetytilcysteine Versus placebo for the prevention of Acute Reduction in Renal function after primary Angioplasty (NoVARA) - NoVARA
- Conditions
- patient with ST elevation myocardial acute infarctionMedDRA version: 9.1Level: SOCClassification code 10007541
- Registration Number
- EUCTR2010-022952-22-IT
- Lead Sponsor
- AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA` DI NOVARA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
patients with aged 18 years and 90 yearsa dmitted in hospital for acute coronary syndrome with persistente ST elevation and chest pain less than 12 hours
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
shock cardiogenic, chronic dialisis, pregnancy, allergy to N-acetylcysteine, inability to obtain informed consent
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: determinate the effects of N-Acetytilcysteine versus placebo to prevent acute reduction in renal function after primary angioplasty;Secondary Objective: not avalable;Primary end point(s): assess the development of contrast induced acute renal failure
- Secondary Outcome Measures
Name Time Method